Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, John Hood, Raymond Rothstein, Leslie Wetzel, Kelly McGlinchey, Grace Adjei, Amanda Watkins, LeeAnn Machiesky, Weimin Chen, John Andrews, Maria Groves, Michelle Morrow, Ross A. Stewart, Andrew Leinster, Robert W. Wilkinson, Scott A. Hammond, Nadia Luheshi, Claire Dobson, Michael Oberst
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2021-01-01
coleção:	mAbs
Assuntos:	PD-L1 CTLA-4 immunotherapy durvalumab tremelimumab murine surrogates
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/19420862.2020.1857100
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!